Detalles de la búsqueda
1.
A complete oral regimen for induction therapy of patients with high-risk APL: An oral etoposide instead of intravenous infusion for cytoreductive chemotherapy.
Br J Haematol
; 2024 Apr 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38671583
2.
PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort study.
Br J Haematol
; 195(5): 722-730, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34405393
3.
Improved survival after offspring donor transplant compared with older aged-matched siblings for older leukaemia patients.
Br J Haematol
; 189(1): 153-161, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31696939
4.
IL-17-producing T cells contribute to acute graft-versus-host disease in patients undergoing unmanipulated blood and marrow transplantation.
Eur J Immunol
; 41(2): 514-26, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21268020
5.
High frequency of CD4+ CD25- CD69+ T cells is correlated with a low risk of acute graft-versus-host disease in allotransplants.
Clin Transplant
; 26(2): E158-67, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22507356
6.
Oral etoposide combined with oral arsenic plus retinoic acid for two cases with newly diagnosed high-risk acute promyelocytic leukemia during COVID19 pandemic.
Leuk Res Rep
; 16: 100258, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34367907
7.
Interferon-α as maintenance therapy can significantly reduce relapse in patients with favorable-risk acute myeloid leukemia.
Leuk Lymphoma
; 62(12): 2949-2956, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34196252
Resultados
1 -
7
de 7
1
Próxima >
>>